FASIDOTRILAT

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C14H17NO5S
Molecular Weight	311.353
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@H](NC(=O)[C@@H](CS)CC1=CC2=C(OCO2)C=C1)C(O)=O

InChI

InChIKey=TXSINLUUGRGAJO-WCBMZHEXSA-N

InChI=1S/C14H17NO5S/c1-8(14(17)18)15-13(16)10(6-21)4-9-2-3-11-12(5-9)20-7-19-11/h2-3,5,8,10,21H,4,6-7H2,1H3,(H,15,16)(H,17,18)/t8-,10+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C14H17NO5S
Molecular Weight	311.353
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://adisinsight.springer.com/drugs/800003997 | https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1527-3466.2000.tb00030.x | https://www.ncbi.nlm.nih.gov/pubmed/14582457

Fasidotril is a diester prodrug of the active metabolite fasidotrilat. Fasidotrilat inhibited both angiotensin I converting enzyme (ACE, EC 3.4.25.1) and neprilysin (NEP, EC 3.4.24.11, also named neutral endopeptidase, enkephalinase, or atriopeptidase) at nanomolar concentrations (Ki = 9.8 nM against ACE and 5.1 nM against NEP) Fasidotril was being developed for the treatment of myocardial infarction, congestive heart failure and myocardial infarction.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Angiotensin-converting enzyme 94 Target ID: P12821 Gene ID: 1636.0 Gene Symbol: ACE Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/1851998	Inhibitor 8504		9.8 nM [Ki]
Neprilysin 29 Target ID: P08473 Gene ID: 4311.0 Gene Symbol: MME Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/1851998	Inhibitor 8504		5.1 nM [Ki]

PubMed

Title	Date	PubMed
Strategies for access to enantiomerically pure ecadotril, dexecadotril and fasidotril: a review.	2002-06	12370063
Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and angiotensin-converting enzyme, in rats and humans.	2000-05	10818079
Effect of long-term therapy with fasidotril, a mixed inhibitor of neprilysin and angiotensin-converting enzyme (ACE), on survival of rats after myocardial infarction.	1999-03	10435026
Hemodynamic effects of acute and chronic treatment with aladotril, a mixed inhibitor of neutral endopeptidase and angiotensin I-converting enzyme, in conscious rats with myocardial infarction.	1995-12	8531099
Mixed inhibitors of angiotensin-converting enzyme (EC 3.4.15.1) and enkephalinase (EC 3.4.24.11): rational design, properties, and potential cardiovascular applications of glycopril and alatriopril.	1991-05-15	1851998

Patents

Sample Use Guides

In Vivo Use Guide

After a 4-week placebo run-in period, 57 patients with essential hypertension were included in a randomized double-blind, placebo-controlled, parallel-group study and received orally either fasidotril (100 mg twice daily) or placebo for 6 weeks.

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Mon Mar 31 23:33:17 GMT 2025` Edited by `admin` on `Mon Mar 31 23:33:17 GMT 2025`
Record UNII	0N48AL0PRA
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FASIDOTRILAT

Common Name

English

ALATRIOPRILAT

Preferred Name

English

L-ALANINE, N-((2S)-3-(1,3-BENZODIOXOL-5-YL)-2-(MERCAPTOMETHYL)-1-OXOPROPYL)-

Systematic Name

English

FASIDOTRIL DIACID [MI]

Common Name

English

Code System Code Type Description

PUBCHEM

9818189